Ratings Beximco Pharmaceuticals Limited London S.E.

Equities

Delayed London S.E. Other stock markets 07:30:01 2024-05-13 EDT			5-day change	1st Jan Change
39 ^GBX	0.00%		+4.00%	-6.02%

04-30	EARNINGS AND TRADING: Software Circle & Beximco report higher revenue	AN
04-30	Beximco Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI

Its low valuation, with P/E ratio at 10.09 and 8.22 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

	1st Jan change	Capi.	ESG Refinitiv
BEXIMCO PHARMACEUTICALS LIMITED	-6.02%	474M	-
ELI LILLY AND COMPANY	+30.38%	684B	C+
NOVO NORDISK A/S	+29.39%	568B	B
JOHNSON & JOHNSON	-4.36%	361B	C+
MERCK & CO., INC.	+19.30%	329B	B-
ABBVIE INC.	+3.73%	284B	C+
ASTRAZENECA PLC	+16.00%	240B	B+
NOVARTIS AG	+9.39%	208B	B-
ROCHE HOLDING AG	-7.28%	200B	A+
AMGEN INC.	+7.68%	166B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality